font measurement
Moderna Covid-19 vaccine.
Yuichi Yamazaki / Getty Photographs
accident
It’s set to report second-quarter earnings on Thursday as the corporate sits on the point of an unsure transition into the industrial Covid-19 vaccine market, with questions looming over how a lot demand stays for the vaccines three years after their launch.
Analysts anticipate
accident
(Inventory ticker: MRNA) reported a lack of $3.93 per share for the quarter, on income of simply $308 million, based on FactSet. The corporate achieved revenues of $4.7 billion in the identical quarter final yr.
Whereas the Covid-19 vaccine has grow to be one of many best-selling medication of all time, with $18.4 billion in gross sales in 2022, Moderna has no different marketed merchandise. The corporate mentioned it expects Covid-19 vaccine gross sales of a minimum of $5 billion in 2023. Analysts anticipate $7.1 billion in gross sales this yr, based on FactSet.
Moderna shares are down almost 40% this yr, as a substitute
Normal & Poor’s 500
almost 20%.
Earlier this yr, Moderna mentioned it anticipated Covid-19 vaccine gross sales of between $200 million and $300 million within the second quarter. Industrial gross sales of the vaccine are anticipated to start this fall, when the corporate will launch an up to date model of the vaccine. Because the first injections got in late 2020, all Covid-19 vaccines in the US have been paid for by the federal authorities. That ended earlier this yr; The federal government is at the moment working by means of its remaining provides.
Moderna’s Covid-19 vaccine competitor
Pfizer
(Inventory ticker: PFE), in its earnings presentation on Tuesday, burdened the uncertainty within the US Covid-19 vaccine market, saying that uptake to this point this yr was decrease than anticipated, however that Pfizer’s market share was barely bigger than anticipated. Pfizer mentioned it will make value cuts if gross sales of its Covid-19 vaccine and therapeutics fall wanting expectations by the tip of the yr.
The state of affairs in Moderna is totally different. The Covid-19 vaccine, Spikevax, was the corporate’s first product marketed. Whereas it has a large pipeline, together with quite a lot of late-stage packages, no product launches are anticipated this yr.
Important Modena pipeline packages embrace a vaccine for respiratory syncytial virus, which may very well be launched in 2024 and would compete with new RSV vaccines from Pfizer and
GSK
(GSK). The corporate can also be anticipating new information on its messenger RNA-based flu vaccine later this yr, and it just lately launched a Section 3 examine in collaboration with
merck
(MRK) her promising Most cancers remedy, mRNA-4157.
Moderna plans to carry investor Name at 8 a.m. on a Thursday to debate the monetary outcomes.
Write to Josh Nathan Kazis at [email protected]
